Finance

Lists
AVLN:NASDAQ
Avalyn Pharma Inc
$37.60
-2.02%
(-0.77) 1D
Aug 24, 11:10:25 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVLN...
Open
$38.49
High
$38.96
Low
$36.63
Mkt. cap
1.67B
Avg. vol.
201.36K
Volume
38.18K
52-wk high
$40.17
52-wk low
$24.15
No. of employees
55
Open
$38.49
High
$38.96
Low
$36.63
Mkt. cap
1.67B
Avg. vol.
201.36K
Volume
38.18K
52-wk high
$40.17
52-wk low
$24.15
No. of employees
55
About Avalyn Pharma Inc
CEO-
Employees55
Founded2011
HeadquartersBoston, Massachusetts, United States
SectorPharmaceutical industry
Websiteavalynpharma.com
Analyst ratings
Based on 3 analysts giving stock ratings to AVLN in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for AVLN in the last 3 months.
Highest
Current $37.60
$57.00 (+51.62%)
Average
$53.33 (+41.85%)
Lowest
$51.00 (+35.66%)
Analyst
Recommendation
Action
Price target
Projected
Date
Roger Song
Jefferies
Buy
Maintained
$52.00
+38.3%
08/13/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
$57.00
+51.6%
08/13/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Initiated
$51.00
+35.7%
05/26/2026
Last report
Aug 12, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
-$0.98 / -$0.48
-104.17%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
15.32M
17.88M
22.89M
24.73M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.40M
3.90M
5.02M
6.56M
Operating expense
18.72M
21.78M
27.91M
31.29M
Total operating expenses
18.72M
21.78M
27.91M
31.29M
Operating income
-18.72M
-21.78M
-27.91M
-31.29M
Other non operating income
-35.00K
-41.00K
13.00K
-69.00K
EBT including unusual items
-17.50M
-20.19M
-26.87M
-28.94M
EBT excluding unusual items
-17.50M
-20.19M
-26.87M
-28.94M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-17.50M
-20.19M
-26.87M
-28.94M
Net profit margin
-
-
-
-
Earnings per share
-
-
-21.83
-0.98
Interest and investment income
1.25M
1.63M
1.12M
2.70M
Interest expense
-
-
-98.00K
-272.00K
Net interest expenses
1.25M
1.63M
1.03M
2.42M
Depreciation and amortization charges
-
-
-
-
EBITDA
-18.71M
-21.77M
-27.85M
-31.18M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps